MPG.eBooks - Table of Contents: Bevacizumab

Read Now

Bibliographic Details
Main Author:	Evans, Tracey L.
Format:	eBook
Language:	English
Published:	London Henry Stewart Talks 2009, 2009
Series:	Cancer therapy : latest thinking in efficacy and toxicity
Subjects:	Neoplasms / Therapy Angiogenesis Inhibitors / Therapeutic Use Neoplasms / Complications Lung Neoplasms / Drug Therapy Carcinoma, Non-small-cell Lung / Drug Therapy
Online Access:	https://hstalks.com/bs/p/385 https://hstalks.com/bs/1113
Collection:	Henry Stewart Talks - Collection details see MPG.ReNa

Table of Contents:

Lung cancer incidence
Survival by treatment group
Selected trials of novel agents + chemotherapy
Bevacizumab
Vascular Endothelial Growth Factor (VEGF)
Principles of angiogenesis
Bevacizumab in NSCLC: not for everybody
Randomized phase II trial of Paclitaxel/Carboplatin with/without Bevacizumab in NSCLC
Hemorrhagic events
Example of tumor cavitation in lung following treatment with chemotherapy and Bevacizumab
Patient haracteristics
Response rates
Hematologic and non-hematologic toxicity
Treatment related deaths
Efficacy by gender and age
NCCN pactice guidelines in oncology-v.2.2008
AVAiL: phase III trial of Bevacizumab + Gemcitabine and Cisplatin in advanced non|squamous cell NSCLC
Second line therapy for advanced NSCLC: the role of Bevacizumab
Adjuvant therapy in NSCLC
Can a broader range of patients be safely treated with Bevacizumab?
Protocol AVF3744g: BRIDGE trial